Chrissy Buteas, President and CEO of the HealthCare Institute of New Jersey, has commented on the recent announcement by the Food and Drug Administration (FDA) regarding the Commissioner’s National Priority Voucher (CNPV) program. This initiative aims to expedite FDA approvals.
Buteas emphasized the extensive time and financial investment required in developing new treatments or cures. “Researching and discovering a new treatment or cure can take a decade or longer and cost billions of dollars. The most important priority is to ensure a product is safe and effective for patients,” she stated. She highlighted the collaborative efforts among researchers, clinicians, and government regulatory agencies in reviewing data to confirm product safety and efficacy.
She further noted that any reduction in review periods that does not compromise safety or efficacy would benefit patients by providing access to new discoveries sooner. “Our companies will continue to partner with FDA and other stakeholders to deliver our life-saving treatments and cures to patients as quickly and as safely as possible,” Buteas added.
